Should I buy or sell Veru stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERU shares. View VERU analyst ratings or view top-rated stocks .

What is Veru's stock price target for 2024?

4 brokerages have issued 12-month price targets for Veru's shares. Their VERU share price targets range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.33 in the next year. This suggests a possible upside of 187.4% from the stock's current price. View analysts price targets for VERU or view top-rated stocks among Wall Street analysts .

How have VERU shares performed in 2024?

Veru's stock was trading at $0.72 at the start of the year. Since then, VERU shares have increased by 61.1% and is now trading at $1.16. View the best growth stocks for 2024 here .

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VERU earnings forecast .

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) released its quarterly earnings data on Monday, April, 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. The company earned $2.14 million during the quarter. Veru had a negative net margin of 405.04% and a negative trailing twelve-month return on equity of 257.92%.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , Corbus Pharmaceuticals (CRBP) , Matinas BioPharma (MTNB) , Organigram (OGI) , Vaxart (VXRT) , Rigel Pharmaceuticals (RIGL) , SCYNEXIS (SCYX) and VBI Vaccines (VBIV) .

Who are Veru's major shareholders?

Veru's stock is owned by many different institutional and retail investors. Top institutional shareholders include 180 Wealth Advisors LLC (0.12%). Insiders that own company stock include Harry Fisch , Lucy Lu and Mario Eisenberger. View institutional ownership trends .

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VERU

Veru (VERU) Stock Price, News & Analysis

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Free VERU Stock Alerts

$1.16

-0.09 (-7.20%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.13
▼
$1.28
50-Day Range: $0.38
▼
$1.79
52-Week Range: $0.36
▼
$1.92

Volume: 2.51 million shs
Average Volume: 2.33 million shs
Market Capitalization: $169.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.33

Get Veru alerts:

Veru MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 187.4% Upside
$3.33 Price Target
Short Interest: Bearish
6.77% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.20
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.32) to ($0.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.17 out of 5 stars

Medical Sector

757th out of 913 stocks

Pharmaceutical Preparations Industry

324th out of 396 stocks

3.4

Analyst's Opinion

Consensus Rating
Veru has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Veru has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.77% of the outstanding shares of Veru have been sold short.
Short Interest Ratio / Days to Cover
Veru has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Veru has recently increased by 4.32%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Veru does not currently pay a dividend.
Dividend Growth
Veru does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERU.

2.9

News and Social Media Coverage

News Sentiment
Veru has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Veru this week, compared to 1 article on an average week.
Search Interest
32 people have searched for VERU on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
15 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veru insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Veru are expected to decrease in the coming year, from ($0.32) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veru is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veru is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veru has a P/B Ratio of 5.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

About Veru Stock (NASDAQ:VERU)

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VERU Stock News Headlines

April 16, 2024 | americanbankingnews.com

Veru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimer

April 1, 2024 | finance.yahoo.com

Veru Announces Date of 2024 Annual Meeting of Shareholders

April 18, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

March 29, 2024 | morningstar.com

Veru Inc

March 22, 2024 | globenewswire.com

Veru Reschedules Annual Meeting of Shareholders

March 21, 2024 | bizjournals.com

Wynwood offices targeted in $102M foreclosure

March 19, 2024 | msn.com

Naksha Saran plays a bike taxi driver in her next film

March 16, 2024 | ca.finance.yahoo.com

VERU Mar 2024 0.500 put

April 18, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

March 12, 2024 | globenewswire.com

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

March 11, 2024 | finance.yahoo.com

VERU Mar 2024 1.500 put

March 9, 2024 | finance.yahoo.com

VERU Jan 2025 17.000 call

March 9, 2024 | finance.yahoo.com

VERU Mar 2024 0.500 call

March 9, 2024 | finance.yahoo.com

VERU Mar 2024 3.000 put

March 1, 2024 | finance.yahoo.com

VERU Mar 2024 2.500 put

February 28, 2024 | msn.com

Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q

February 27, 2024 | globenewswire.com

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

February 25, 2024 | benzinga.com

Veru Stock (NASDAQ:VERU), Analyst Ratings, Price Targets, Predictions

February 20, 2024 | finance.yahoo.com

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

February 20, 2024 | globenewswire.com

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

February 16, 2024 | finance.yahoo.com

VERU Feb 2024 0.500 call

February 15, 2024 | investorplace.com

The 3 Best Penny Stocks to Buy in February 2024

February 14, 2024 | ca.finance.yahoo.com

VERU Apr 2024 3.000 call

February 13, 2024 | finance.yahoo.com

After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)

February 13, 2024 | finance.yahoo.com

VERU Feb 2024 1.000 call

February 13, 2024 | finance.yahoo.com

VERU Jul 2024 2.000 call

February 9, 2024 | msn.com

FDA clears Veru’s IND for GLP-1 RA-associated muscle loss drug

See More Headlines

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/02/2021
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Personal Products
Current Symbol: NASDAQ:VERU
CUSIP: 31446210
CIK: 863894
Web: www.veruhealthcare.com
Phone: (305) 509-6897
Fax: 312-595-9122
Employees: 189
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.33
High Stock Price Target: $5.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +187.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,150,000.00
Net Margins: -405.04%
Pretax Margin: -390.73%
Return on Equity: -257.92%
Return on Assets: -107.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.21
Quick Ratio: 2.79

Sales & Book Value

Annual Sales: $16.30 million
Price / Sales: 10.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.22 per share
Price / Book: 5.27

Miscellaneous

Outstanding Shares: 146,380,000
Free Float: 125,595,000
Market Cap: $169.80 million
Optionable: Optionable
Beta: -0.21

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Mitchell S. Steiner F.A.C.S. (Age 63)
M.D., Chairman, President & CEO
Comp: $885.32k
Dr. Harry Fisch F.A.C.S. (Age 65)
M.D., Vice Chairman & Chief Corporate Officer
Ms. Michele Greco (Age 65)
CFO & Chief Administrative Officer
Comp: $493.7k
Dr. K. Gary Barnette Ph.D. (Age 56)
Chief Scientific Officer
Comp: $676.27k
Mr. Samuel Fisch
Executive Director of Investor Relations & Corporate Communications
Mr. Michael J. Purvis
Executive VP, General Counsel & Corporate Strategy and Secretary
Mr. Kevin J. Gilbert CPA
J.D., Executive Vice President of Corporate Development
Mr. Martin Tayler (Age 55)
Executive Vice President of FC2 Global Operations
Comp: $180.51k
Mr. Philip R. Greenberg J.D.
Executive VP & Deputy General Counsel
Dr. Domingo Rodriguez M.D. (Age 62)
Executive Vice President of Global Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VERU Stock Analysis - Frequently Asked Questions

Should I buy or sell Veru stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERU shares.
View VERU analyst ratings or view top-rated stocks.
What is Veru's stock price target for 2024?: 4 brokerages have issued 12-month price targets for Veru's shares. Their VERU share price targets range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.33 in the next year. This suggests a possible upside of 187.4% from the stock's current price.
View analysts price targets for VERU or view top-rated stocks among Wall Street analysts.
How have VERU shares performed in 2024?: Veru's stock was trading at $0.72 at the start of the year. Since then, VERU shares have increased by 61.1% and is now trading at $1.16.
View the best growth stocks for 2024 here.
When is Veru's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VERU earnings forecast.

How were Veru's earnings last quarter?: Veru Inc. (NASDAQ:VERU) released its quarterly earnings data on Monday, April, 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. The company earned $2.14 million during the quarter. Veru had a negative net margin of 405.04% and a negative trailing twelve-month return on equity of 257.92%.
What other stocks do shareholders of Veru own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).
Who are Veru's major shareholders?: Veru's stock is owned by many different institutional and retail investors. Top institutional shareholders include 180 Wealth Advisors LLC (0.12%). Insiders that own company stock include Harry Fisch, Lucy Lu and Mario Eisenberger.
View institutional ownership trends.
How do I buy shares of Veru?: Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERU) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Veru (VERU) Stock Price, News & Analysis

Veru MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Veru Stock (NASDAQ:VERU)

VERU Stock Price History

VERU Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

VERU Stock Analysis - Frequently Asked Questions

Overall MarketRank^™